贝那普利联合曲美他嗪治疗冠心病慢性心力衰竭的效果

Application effect of benazepril combined with trimetazidine in the treatment of coronary heart disease of chronic heart failure

目的研究贝那普利联合曲美他嗪治疗冠心病慢性心力衰竭的效果。方法选取2015年1月至2017年1月入院治疗的90例冠心病慢性心力衰竭患者,根据治疗方法分为研究组和对照组,各45例。对照组采用贝那普利进行治疗,研究组采用贝那普利与曲美他嗪联合治疗。比较两组患者治疗前、后的心率(HR)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、临床疗效和不良反应发生情况。结果治疗后,两组患者的HR、LVEDD及LVEF均显著改善,且研究组优于对照组(P<0.05);研究组的治疗总有效率为97.78%,明显高于对照组的82.22%(P<0.05);两组患者治疗后的不良反应发生率比较,差异不显著(P>0.05)。结论采用贝那普利联合曲美他嗪治疗冠心病慢性心力衰竭效果显著,值得临床推广应用。

Objective To study application effect of benazepril combined with trimetazidine in the treatment of coronary heart disease of chronic heart failure. Methods A total of 90 patients with coronary heart disease of chronic heart failure in our hospital from January 2015 to January 2017 were selected and divided into control group and study group according to the treatment methods, with 45 cases in each group. The control group was treated with benazepril,and the study group was treated with benazepril combined with trimetazidine. The clinical effects, incidences of adverse reactions and the heart rate（HR）, left ventricular end diastolic dimension（LVEDD）, left ventricular ejection fraction（LVEF） before and after treatment in the two groups were compared. Results After treatment, the levels of HR, LVEDD and LVEF in the two groups improved, and those of the study group were significantly better than the control group（P0.05）. The total effective rate of treatment in the study group was 97.78%, which was higher than 82.22% in the control group（P0.05）. There was no significant difference in the incidence of adverse reactions after treatment between the two groups（P0.05）. Conclusion Benazepril combined with trimetazidine in the treatment of coronary heart disease of chronic heart failure has significant effect, and it is worthy of clinical application.